Orforglipron vs Tirzepatide: Pill vs Injection, Explained

Orforglipron and tirzepatide both show up in GLP-1 conversations, but they’re not the same kind of drug or the same kind of routine. One is a daily pill; the other is a weekly injection with a different mechanism entirely. Here’s how they actually compare — mechanism, route, dosing, and side effects — without inventing numbers neither drug has a verified head-to-head trial to back up.

What each one is

Orforglipron (brand Foundayo, Eli Lilly) is a once-daily oral GLP-1 receptor agonist — a small molecule, not a peptide, which is part of why it doesn’t need the injection or the strict food/water rules some oral peptides require. It’s FDA-approved for chronic weight management in adults with obesity, or overweight with at least one weight-related condition, alongside diet and physical activity.

Tirzepatide (brands Zepbound and Mounjaro, also Eli Lilly) is a once-weekly subcutaneous injection and a dual GIP and GLP-1 receptor agonist — it acts on two gut-hormone receptor pathways instead of one. Per MedlinePlus, it’s used for type 2 diabetes blood sugar control (Mounjaro), for weight loss in adults with obesity or overweight plus a weight-related condition (Zepbound), and for obstructive sleep apnea in adults with obesity (Zepbound). It belongs to a drug class MedlinePlus labels “incretin mimetics.”

So the first real difference isn’t pill-vs-shot — it’s mechanism. Orforglipron works through one receptor; tirzepatide works through two.

Side-by-side comparison

	Orforglipron (Foundayo)	Tirzepatide (Zepbound / Mounjaro)
Drug class	GLP-1 receptor agonist (small molecule)	Dual GIP + GLP-1 receptor agonist
Route	Oral tablet	Subcutaneous injection
Frequency	Once daily	Once weekly
Brand(s)	Foundayo	Zepbound (weight/OSA), Mounjaro (type 2 diabetes)
Administration	Any time of day, with or without food, no water restriction	Injected in abdomen, thigh, or upper arm; rotate sites each dose; with or without meals, any time of day
Typical dose escalation	0.8 → 2.5 → 5.5 → 9 → 14.5 → 17.2 mg, each step held ≥30 days	Started low, increased gradually, “not more than often every 4 weeks” per MedlinePlus
Storage	Oral tablet (see label for storage details)	Refrigerated 36–46°F; unused pens/vials can sit at room temperature up to 21 days
Common side effects	Gastrointestinal — nausea, vomiting, constipation, diarrhea	Gastrointestinal — nausea, vomiting, diarrhea, decreased appetite, constipation, upset stomach

Sources: FOUNDAYO FDA label (DailyMed) and MedlinePlus tirzepatide injection page — both linked below.

The convenience angle: pill vs injection

This is the part people usually care about day to day. A daily pill and a weekly injection ask completely different things of you:

• Frequency of the “did I do it” moment. Orforglipron needs a decision every day, seven days a week. Tirzepatide needs one decision a week, but it’s higher-stakes if you forget it — there’s no “catch up tomorrow.”
• No needles, no cold chain. Orforglipron travels like any tablet — no refrigeration, no sharps disposal, nothing to inject. Tirzepatide requires keeping the injection cold (or tracking the 21-day room-temperature window), rotating injection sites, and handling a needle each week.
• Titration length. Orforglipron’s schedule (roughly six steps, each held a month or more) can stretch to several months before reaching a stable dose. Tirzepatide’s dose is also raised gradually — no more often than every 4 weeks per MedlinePlus — so both involve a multi-month ramp, just on different rhythms.
• Privacy and logistics. Swallowing a tablet is invisible. An injection, even a small at-home one, takes a few minutes of prep and a private moment.

Neither routine is objectively “easier” — they’re different failure modes. A weekly shot is easy to remember but costly to miss; a daily pill is low-stakes per dose but easy to let slide into “most days” instead of “every day.” For a deeper look at this tradeoff across all oral vs. injectable GLP-1s, see GLP-1 Pill vs Injection: What’s Actually Different.

Who each approach might suit

This is general, educational framing — not a recommendation for your situation:

• Orforglipron may suit people who want to avoid needles entirely, who travel often and don’t want cold-chain logistics, or who prefer the routine of a daily habit (like a daily vitamin) over remembering a single weekly event.
• Tirzepatide may suit people who prefer fewer total dosing decisions per week, who are comfortable with self-injection, or whose prescriber determines the dual GIP/GLP-1 mechanism is the better clinical fit for their specific health profile — including type 2 diabetes management (Mounjaro) or obstructive sleep apnea (Zepbound), indications orforglipron does not currently carry.

Because there is no verified, direct head-to-head clinical trial comparing orforglipron and tirzepatide on weight-loss outcomes, this article deliberately doesn’t cite a “X% vs Y%” efficacy comparison — that number doesn’t currently exist in a form that can be verified against a real trial, and inventing one would be misleading. If you want efficacy figures, ask your prescriber, who can point you to each drug’s actual trial data and how it applies to you.

The bottom line

Orforglipron and tirzepatide are both GLP-1-pathway medications from Eli Lilly, but they differ in mechanism (single vs. dual receptor), route (pill vs. injection), frequency (daily vs. weekly), and approved uses (tirzepatide currently covers type 2 diabetes and obstructive sleep apnea in addition to weight management; orforglipron’s approval to date is for weight management). Both share a similar side-effect profile dominated by GI symptoms that tend to appear during dose increases.

If you’re weighing one against the other — or a switch from one to the other — talk to your prescriber. They can factor in your health history, other conditions, insurance coverage, and how you’ve responded to any GLP-1 so far, which is the only way to make this decision well.

For more on orforglipron specifically, see Foundayo (Orforglipron): A Simple Guide.